Detalhe da pesquisa
1.
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
N Engl J Med
; 384(14): 1289-1300, 2021 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33616314
2.
Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.
Gynecol Oncol
; 186: 182-190, 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38718741
3.
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 24(12): 1399-1410, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38039993
4.
Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.
J Hepatol
; 78(1): 133-141, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36341767
5.
Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma.
Br J Cancer
; 124(1): 237-246, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33024271
6.
The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors.
Future Oncol
; 17(6): 637-648, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33300372
7.
Second-line lenvatinib in patients with recurrent endometrial cancer.
Gynecol Oncol
; 156(3): 575-582, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31955859
8.
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
Lancet Oncol
; 20(5): 711-718, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30922731
9.
Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma.
Br J Cancer
; 121(7): 625, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31363170
10.
Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma.
Br J Cancer
; 121(3): 218-221, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31249394
11.
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Lancet
; 391(10126): 1163-1173, 2018 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-29433850
12.
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale.
Future Oncol
; 15(9): 929-941, 2019 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-30689402
13.
A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
Future Oncol
; 15(7): 717-726, 2019 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-30638399
14.
Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
Cancer
; 124(11): 2365-2372, 2018 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29656442
15.
Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study.
Br J Cancer
; 118(12): 1580-1585, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29867224
16.
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
N Engl J Med
; 372(7): 621-30, 2015 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-25671254
17.
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.
Lancet Oncol
; 16(15): 1473-1482, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26482279
18.
Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer.
Oncologist
; 19(4): 318-27, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24682463
19.
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146.
J Immunother Cancer
; 12(1)2024 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38242717
20.
A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update.
J Clin Oncol
; 41(5): 974-979, 2023 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36608305